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Summary: The great majority of individuals with hu- 
man immunodeficiency virus type 1 (HIV-1) infection 
presents with no signs or symptoms, or only lymphade- 
nopathy. To initiate prophylactic measures in time it is 
necessary to establish risk criteria. CD4 + cell counts 
are significant predictors. Supplementary methods to 
improve the predictive information f CD4+ cell 
counts are still required. In addition, CD4 + cell count- 
ing is laborious, expensive, and restricted to specializ- 
ed laboratories. Thus, there is also a place for more 
easily performed laboratory tests with similar predictive 
value as CD4 + cell counts. Neopterin and [32-micro- 
globulin levels proved to be significant predictors of 
AIDS risk in HIV-1 seropositives. The predictive value 
Zusammenfassung: Neopterin und ~2-Mikroglobulin als 
Prognoseindices bei Infektionen mit dem humanen Im- 
munschwiichevirus Typ I (H1V-1). Die Mehrheit der mit 
dem humanen Immundefizienzvirus Typ 1 (HIV-1) in- 
fizierten Personen ist frei von Symptomen oder weist 
nur persistierende Lymphadenopathie auf. Es ist not- 
wendig, Risikokriterien fiir das Fortschreiten der Er- 
krankung zu erstellen, um zeitgerecht prophylaktische 
Mal3nahmen einleiten zu k6nnen. Die Zahl der CD4- 
positiven Zellen ist ein geeigneter Prognoseparameter. 
Die Zellz~hlung ist jedoch aufwendig, teuer und Spezi- 
allabors vorbehalten, sodal3 zusfitzliche infache Unter- 
suchungen erwfinscht sind, um die Risikoabschfitzung 
weiter zu verbessern. Wissenschaftliche Untersuchun- 
gen ergaben, dab Neopterin und 132- Mikroglobulin bei 
der HIV-1 Infektion gleich gute Prognoseparameter 
sind wie die Zahl der CD4-positiven Zellen; beide Pa- 
of both parameters i equal to CD4 + cell counts and 
both markers are significant joint predictors in addition 
to CD4 + cell counts. Measurement of the parameters 
is done in serum (neopterin and [32-microglobulin) or 
urine (neopterin) specimens which reduces the risk of 
HIV-1 transmission compared to handling of whole- 
blood samples as it is required for cell counting. Al- 
though more studies are needed, especially in devel- 
oping countries and in persons receiving zidovudine, it
can be recommended to use neopterin and [32-micro- 
globulin as additional marker to estimate AIDS risk in 
HIV-1 seropositive individuals. Moreover, both mark- 
ers may be useful for this purpose without CD4 + cell 
counts if cell counting is not available. 
rameter liefern dartiber hinaus zusfitzliche Informati- 
on. Die Bestimmung der Mel3grfBen erfolgt aus Serum 
(Neopterin und 132-Mikroglobulin) oder Urin (Neopte- 
rin), wodurch das Risiko einer eventuellen HIV-1 
Obertragung bei der Testdurchftihrung im Vergleich 
zur Bearbeitung von Vollblut, wie es zur Zellzfihlung 
ben6tigt wird, verringert wird. Auch wenn noch weitere 
Untersuchungen vor allem in Entwicklungslfindern u d 
in mit Zidovudin behandelten HIV-1 Infizierten not- 
wendig sind, k6nnen Neopterin und 132-Mikroglobulin 
als zus~tzliche Parameter zur Abschfitzung des AIDS- 
Risikos bei HIV-1 Infizierten empfohlen werden. Bei- 
de Mel3gr613en sind auch dazu geeignet, die Bestim- 
mung von CD4- positiven Zellen zu ersetzen, wenn die 
M6glichkeiten der Zellquantifizierung nicht gegeben 
sind. 
Introduction 
Human immunodeficiency virus type 1 (HIV-1) is the 
causative agent for the acquired immunodeficiency s n- 
drome (AIDS). Today the diagnosis of HIV-1 infection 
can routinely be performed with more than 95% diagnos- 
tic sensitivity and specificity of the available test systems. 
From the first epidemiologic surveys it became evident 
that the great majority of individuals who were diagnosed 
as HIV-1 seropositive presented with no signs or symp- 
toms or only with lymphadenopathy. Follow-up studies 
performed in cohorts of homosexual men, haemophilia p - 
tients, and intravenous drug users (IVDU) showed an an- 
nual AIDS progression rate of HIV-1 seropositives be- 
tween 5-10% [1]. To allow early initiation of prophylactic 
measures in HIV-1 seropositives, indicators of disease 
progression are required for monitoring of HIV-1 seropos- 
itive individuals. By this strategy, it is hoped to prevent or 
at least delay the onset of opportunistic nfections in sub- 
jects at increased risk for AIDS. 
Progressive HIV-1 infection is associated with a steady 
decline of CD4 + cell numbers [2], and a low number of 
CD4 + cells is a predictive marker of an increased risk for 
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Figure 1 Neopterin (6-D-erythro-trihydroxypropylpterin). 
disease progression in HIV-1 seropositives [3, 4]. How- 
ever, counting of CD4 + cells is laborious, time-consuming 
and expensive. Therefore, it is important o develop sup- 
plementary or alternative methods which are more readily 
available to clinical laboratories and which are easily per- 
formed. Of course, such tests need to indicate an in- 
creased risk for AIDS among HIV-1 seropositives with 
similar sensitivity and specificity as CD4 + cell counting 
does. 
Neopterin 
Biosynthetically D-erythro-neopterin (Figure 1) derives 
from guanosinetriphosphate. In vitro, human macrophages 
produce and release large amounts of neopterin on stimu- 
lation with interferon gamma. Increased neopterin con- 
centrations have been demonstrated in patients with dis- 
eases associated with or caused by cell-mediated immune 
activation [5, 6] as with allograft rejections, autoimmune 
disorders, infections by viruses, intracellular bacteria nd 
parasites, and certain types of malignant tumours. 
In general, neopterin concentrations reflect he extent and 
the activity of the disease. Therefore, neopterin is a useful 
marker to monitor therapy in patients. In patients with 
malignant turnouts, a significant predictive value of neop- 
terin was demonstrated byseveral investigators [reviewed 
in reference 5]. 
Measurement ofneopterin in body fluids such as urine, se- 
rum, cerebrospinal fluid (CSF) is usually done by commer- 
cially available immunoassays or high pressure liquid chro- 
matography (HPLC) techniques. Neopterin concentra- 
tions in spot urine samples are related to creatinine levels 
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[52-Microglobulin (B2M) is a low molecular weight protein 
of 11,800 Dalton. It is the light chain of the major histo- 
compatibility complex (MHC) class I antigens HLA-A, 
HLA-B, and HLA-C. MHC class I antigens are expressed 
on the surface of all normal nucleated cells, being present 
in highest density on lymphocytes. Shedding of B2M from 
cells is enhanced uring proliferation and differentiation. 
Recently, it was shown that B2M possesses chemotactic 
activity for lymphoid cells and that it is identical with thy- 
motaxin [7]. 






Figure 2: Urinary neopterin concentrations in individuals with 
different stages of HIV-1 infection. 
Serum B2M levels are increased indiseases characterized by
increased cell turnover, like malignancy [8] and chronic in- 
flammation, e.g., rheumatic diseases and infections, but may 
be due also to renal impairment. Stimulation of immune 
cells, preferentially of lymphocytes [9] and macrophages, 
and the activity of specific ytokines such as interferon gam- 
ma [10] contribute to B2M increase via enhancement of
MHC class I expression on target cells. 
For diagnostic purposes, B2M levels in body fluids are usual- 
ly quantified using commercially available immunoassays. 
Evaluation of Neopterin in HIV-1 Infection 
In 1983 increased neopterin concentrations were reported 
in urine of patients with AIDS and with generalized 
lymphadenopathy [11]. The increase of serum and urine 
neopterin concentrations parallels disease progression in 
HIV-1 seropositives, and a significant association between 
neopterin and various staging classification systems was 
found [6, 12, see Figure 2]. Asymptomatic HIV-1 seropos- 
itives have increased neopterin levels with high percentage 
compared to HIV-1 seronegative blood donors. Neopterin 
concentrations correlate negatively with CD4 + cell counts 
in HIV-1 seropositives [13], and neopterin levels were 
found to be at least equally sensitive and specific as CD4 + 
cell counts to discriminate between HIV-1 seropositive 
and seronegative homosexuals [13, 14]. As was shown in 
retrospective analyses of sequentially collected samples 
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Table 1 : The time-dependent posterior probability for AIDS as a 
function of urinary neopterin levels (~tmol neopterin per mol 
creatinine). 
• i ii i ii: i i i i iiiiiiii 
200 1.64% 4.94% 9.51% 16.2% 
400 3.89% 10.7 % 18.8 % 31.1% 
800 '19.3 % 39.0 % 54.9 % 71.3% 
1200 58.5 % 77.3 % 86.5 % 93.2% 
from HIV-1 seroconverters, a higher increase of serum ne- 
opterin concentrations after exposure to HIV-1 was asso- 
ciated with a more rapid subsequent fall of CD4 + cell 
counts [15]. 
Prospective and retrospective analyses showed that neop- 
terin concentrations in urine [16, 17] and serum [15, 
18-20] are significant predictors for the onset of AIDS in 
HIV-1 seropositives. Serum or urine measurements are of 
equal value [21], and it turned out according to all surveys 
that neopterin concentrations are of similar predictive sig- 
nificance as CD4 + cell counts. Moreover, neopterin con- 
centrations and CD4 + cell counts are significant joint 
predictors for the onset of AIDS. Thus, measurement of 
neopterin to predict prognosis in HIV-1 seropositives pro- 
vides information which is of similar significance as CD4 + 
cell counts and adds significant information when being 
used in addition to CD4 + cell counting. 
However, grouped data only allow statistical analysis of 
the predictive potential of a laboratory parameter. For 
prospective monitoring of HIV-1 seropositive individuals 
it is necessary to use an individual AIDS-risk estimate 
composed of single or multiple laboratory parameters. 
Bogner et al. concluded from their data that serum neopte- 
fin levels above 22nmol/1 may indicate the manifestation f 
AIDS in the year to come [18]. Table 1 shows the result of 
a calculation of AIDS risk based on urine neopterin data 
from reference 17. In contrast to CD4 + cell counts (not 
shown), neopterin levels provide an AIDS-risk estimate 
for several years (Table 1): The AIDS risk correlates with 
the height of urine neopterin levels and increases with 
time (Reibnegger et al., Clin. Chem., in press). 
Evaluation of [32-Microglobulin in HIV-1 Infection 
In 1983 increased serum B2M levels were reported in pa- 
tients with AIDS [22]. Subsequently, B2M levels were de- 
scribed as increasing with the stage of HIV-1 infection [23, 
24]. In contrast to neopterin results, B2M levels increase 
to abnormal levels preferentially in advanced stages of 
HIV-1 infection, whereas the great majority of asympto- 
matic HIV-1 seropositives presents with B2M levels below 
2.5 mg/l, which is the 95th percentile of HIV-1 seronega- 
tive controls [19, 25], The B2M mean value in AIDS pa- 
tients is approximately four times the mean value of 
HIV-1 seronegative controls (Figure 3). 
Retrospective analyses of HIV-1 seroconverters showed 
that the change of B2M after exposure to HIV-1 is associ- 
ated with the decline of CD4 + cell counts during the fol- 
lowing months [25]. 
Retrospective studies further demonstrated that serum 
B2M concentration is a significant predictor of AIDS in 
HIV-1 seropositives [19, 20, 25, 26]. In all surveys B2M 
levels turned out to be of similar value as CD4+cell 
counts for predicting the onset of AIDS in HIV-1 sero- 
positive individuals. Moreover, B2M predicted disease 
progression i dependently from CD4 + cell counts. Both 
markers are significant joint predictors. 
Neopterin and/or [32-Microglobulin to Predict the Onset of 
AIDS in HIV-1 Seropositive Individuals 
Serum and urine neopterin and serum B2M levels behave 
similarly during the course of HIV-1 infection. The rela- 
tive increase during HIV-1 infection compared to baseline 
levels of HIV-1 seronegative controls is higher for neopte- 
fin (10-fold increase, Figure 2) compared to B2M changes 
(Figure 3). Neopterin reaches earlier abnormal evels 
during the course of HIV-1 infection than B2M. However, 
correlation coefficients up to 0.8 were observed in studies 
comparing both markers (Figure 4). 
Neopterin and B2M are of similar value as CD4 + cell 
counts to predict disease progression i  prevalent HIV-1 
seropositives. In a study of various erologic and immuno- 
logic markers to predict he onset of AIDS [19], relative- 
hazard characteristics were again similar for CD4 + cells 
(log- likelihood = -456.65), CD4 + percentage (-455.70), 
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Figure 3: Serum 132-microglobulin concentrations in individuals 
with different stages of HIV-1 infection. 
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Figure 4: Correlation between serum neoptefin and ~2-micro- 
globulin in 99 HIV-1 seropositive individuals (Spearman 
rank correlation coefficient rs = 0.744, P<.O01). 
CD4 +/CD8 + cell ratio (-454.21) and neopterin 
(-457.74), when the parameters were applied as single 
predictors (the less negative the log-likelihood, the more 
significant is the corresponding variable). B2M (-464.35), 
soluble interleukin-2 receptor (slL-2r; -465.98), and IgA 
(-464.20) had weaker potential to predict AIDS. 
In combination with CD4 + cell counts, neopterin or B2M 
were of identical value (log-likelihood = -448.17 and 
-449.45, respectively). In this study, the best combination 
of markers to model the risk of AIDS consisted of CD4 + 
cells, neopterin, slL-2r, IgA and (presence or absence of) 
p24 antigen (- 432.31). 
Retrospective time-dependent analyses in a cohort of ho- 
mosexual men [20] showed that the CD4 + cell percentage 
significantly predicted AIDS onset 48-60 months before 
diagnosis (p=0.008). Serum neopterin (p<0.001) and 
B2M (p = 0.02) became significant 24-36 months before 
onset of AIDS; 2-12 months before the diagnosis of AIDS, 
B2M was the best single predictor (p<0.001). In agree- 
ment with this, a prospective study showed a significant 
predictive value during six years for urine neopterin con- 
centrations [17]. 
Conclusions 
Neopterin and B2M are useful laboratory parameters to 
define AIDS risk in HIV-l-seropositive individuals. Both 
parameters reflect immune activation in patients, and 
therefore, changes of neopterin and B2M are not specific 
for HIV-1 infection. Although variation of CD4+ cell 
counts can be considered a significant aspect of HIV-1 pa- 
thology, the predictive value of neopterin and B2M equals 
that of CD4 + cell counts. Therefore, and because they 
are significant predictors jointly with CD4 + cell number, 
neopterin and/or B2M can be recommended asadditional 
markers to improve the estimation of AIDS risk in HIV-1 
seropositives even when CD4 + cell counts are available. 
Moreover, neopterin and B2M are likely to be of consider- 
able value if CD4 + cell counting is not available, although 
the predictive value of these assays in developing nations, 
and to a lesser extent in IVDUs, remains to be proven. In 
addition, these markers may be valuable for monitoring 
therapy with zidovudine [27-29]. 
In combination with CD4 + cell counts, neopterin and 
B2M are of similar value to estimate prognosis. When 
used as single parameters, neopterin appears to be slightly 
more sensitive to indicate immunological alterations in 
HIV-1 seropositive compared to HIV-1 seronegative indi- 
viduals during the early course of infection [19, 20]. How- 
ever, in prospective follow-up of HIV-1 seroconverters 
both markers, neopterin and B2M, were significantly pre- 
dictive for the onset of AIDS even one year after serocon- 
version [30]. Additional studies are required to further 
clarify this point. 
The possibility to establish more accurate risk criteria in 
HIV-1 seropositive individuals may help to optimize pro- 
phylactic measures in patients and to select even asympto- 
matic patients, who are at greater isk for AIDS, for anti- 
retroviral treatment. 
Measurement of neopterin and B2M is feasible using only 
a few microliters of serum. Immunoassays can be per- 
formed outside of specialized laboratories, and samples 
can be posted from the periphery to the laboratory for 
measurement. Handling and pipetting of serum samples is 
less infectious than of whole blood, and the risk of HIV-1 
transmission is close to zero when using urine samples for 
neopterin measurements. 
Importantly, neopterin concentrations correlate signifi- 
cantly with virus isolation frequency in patients and with 
reverse transcriptase activity of HIV-1 isolates [31]. More- 
over, neopterin values correlate significantly and positively 
with circulating interferon gamma levels in HIV-1 sere- 
positives [32]. The significance of neopterin and B2M to 
monitor and even to predict he course of HIV-1 infection 
underlines the relevance of immune activation for the patho- 
genesis of the disease [6]. In patients, immune activation 
may upregulate HIV-1 reproduction i infected cells. It is 
necessary to recognize that chronic activation is ongoing at 
a high level in HIV-1 seropositives. The higher the degree 
of activation, even in asymptomatic individuals, the more 
rapidly disease progression will develop. 
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